COMPUGEN REPORTS NET LOSS OF $3.0 MIL FOR 2ND QTR 2008.

Compugen Ltd. (NASDAQ: CGEN), Tel Aviv, Israel, has reported its results for the second quarter ending June 30, 2008.

Compugen President and CEO Alex Kotzer stated, "During this past quarter, the diversity of our unique prediction-based discovery efforts continued to be demonstrated with the disclosure of successful experimental validation results for novel biomarkers for the early preclinical detection of drug-induced kidney toxicity, for more than 10 drug target candidates for cancer antibody therapeutics, for a therapeutic peptide candidate for immune related diseases and for three G-Protein coupled receptor (GPCR) ligands."

Kotzer continued, "More recently, Compugen announced the successful completion of in vitro and in vivo validation tests for CGEN-50001, a drug that has been marketed for many years in Europe for central nervous system indications such as depression. In these recently completed studies, the drug, which is neither marketed nor approved for usage in the US, was shown to significantly increase the effect of Tamoxifen, a frequently used drug for the treatment of estrogen receptor (ER) positive breast cancer. The beneficial impact of administering CGEN-50001 in this completely unrelated and very major medical condition was initially predicted in silico by our New Indications Discovery Platform. CGEN-50001 was then selected for further validation. Following the positive results, we are now planning a proof of concept human trial for this new usage as well as evaluating other drugs with potential new usages that have been predicted by this very powerful platform."

Compugen also announced the appointment of Dikla Czaczkes Axselbard as chief financial officer, succeeding Ronit Lerner who resigned from the company. Czaczkes Axselbard served as director of finance for Compugen from 2002 through 2007, and as acting CFO since February 2008. Prior to joining Compugen, Czaczkes Axselbard was chief financial officer of Packet Technologies Ltd, a mobile internet security hardware and software startup company and before that an audit manager at Ernst & Young Israel. She holds an MBA in finance and a BA in accounting and economics, both from the Tel Aviv University, and is a certified public accountant in Israel.

Revenues for the second quarter of 2008 were $40,000 and for the six months ended June 30, 2008, were $321,000. No revenues were reported for either of the comparable periods of 2007.

The net loss for the most recent quarter was $3.0 million (including a non-cash expense of $416,000 related to stock based compensation) or $0.10 per share, compared with a net loss of $3.2 million (including a non-cash expense of $436,000 related to stock based compensation), or $0.11 per share, for the corresponding quarter of 2007. The net loss for the first six months of 2008 was $5.5 million (including a non-cash expense of $743,000 related to stock based compensation), or $0.19 per share, compared with a net loss of $6.3 million (including a non-cash expense of $1.2 million related to stock based compensation), or $0.22 per share, for the same period in 2007.

Research and development expenses of $2.4 million for the second quarter of 2008, compared to $2.3 million for the second quarter of 2007, remain the company's largest expense, representing approximately 70% of total expenses. These amounts are before the deduction of governmental and other grants, which totaled $169,000 for the second quarter ended June 30, 2008, compared with $293,000 for the corresponding quarter in 2007.

In view of the increase in the market value of the company's holding in Evogene Ltd, this amount is now shown as a separate line item in the company's consolidated balance sheets and was $4.6 million as of June 30, 2008 compared to $510,000 at year end 2007. Previously, the company's holding in Evogene was included in Other Assets.

As of June 30, 2008, Compugen had $12.6 million in cash, cash equivalents, deposits and marketable securities, a decrease of $4.6 million from the $17.2 million reported as of December 31, 2007.

About Compugen

Compugen's mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The company's increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery - field after field - of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the company's decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen's current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA), to utilize the company's in-silico predictive discovery capabilities in the agricultural biotechnology field.

For more information, visit Compugen's corporate Website at www.cgen.com and Evogene's corporate Website at www.evogene.com.